Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Other Non-Current Liabilities: 2012-2025

Historic Other Non-Current Liabilities for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to $260,000.

  • Enanta Pharmaceuticals' Other Non-Current Liabilities rose 12.55% to $260,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $260,000, marking a year-over-year increase of 12.55%. This contributed to the annual value of $260,000 for FY2025, which is 12.55% up from last year.
  • Enanta Pharmaceuticals' Other Non-Current Liabilities amounted to $260,000 in FY2025, which was up 12.55% from $231,000 recorded in FY2024.
  • In the past 5 years, Enanta Pharmaceuticals' Other Non-Current Liabilities ranged from a high of $663,000 in FY2023 and a low of $231,000 during FY2024.
  • In the last 3 years, Enanta Pharmaceuticals' Other Non-Current Liabilities had a median value of $260,000 in 2025 and averaged $384,667.
  • Per our database at Business Quant, Enanta Pharmaceuticals' Other Non-Current Liabilities skyrocketed by 46.04% in 2023 and then plummeted by 65.16% in 2024.
  • Enanta Pharmaceuticals' Other Non-Current Liabilities (Yearly) stood at $558,000 in 2021, then fell by 18.64% to $454,000 in 2022, then spiked by 46.04% to $663,000 in 2023, then plummeted by 65.16% to $231,000 in 2024, then grew by 12.55% to $260,000 in 2025.